Overview

Regorafenib in Metastatic Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Rochester

Collaborator:

Bayer